Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Drop in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a large decrease in short interest in November. As of November 15th, there was short interest totalling 30,900 shares, a decrease of 84.2% from the October 31st total of 195,700 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 1,720,000 shares, the short-interest ratio is currently 0.0 days.

Windtree Therapeutics Trading Up 8.2 %

Windtree Therapeutics stock opened at $0.61 on Thursday. The stock has a 50 day moving average of $1.12 and a 200-day moving average of $3.88. The stock has a market cap of $359,782.00, a P/E ratio of -0.02 and a beta of 0.64. Windtree Therapeutics has a 52 week low of $0.45 and a 52 week high of $22.36.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.